Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects will be informed about the study, have read, understood, and signed the Informed Consent Form~2. Subjects of either gender that are ≥18 years of age~3. Subjects who can ambulate preoperatively~4. Subjects will have a Body-Mass Index (BMI) of ≤ 40mg/m2~5. Subjects with an American Society of Anesthesiologists (ASA) classification of 1, 2 or 3~6. Subjects not receiving an epidural to control perioperative pain~7. Subjects will be undergoing elective single-staged open ventral (incisional or midline) hernia repair~8. Subjects in which intra-operatively their surgical field/wound is characterized as Type 1 (Appendix II)~9. Subjects with a hernia defect ≥9 cm2 large~Exclusion Criteria:~1. Subjects who are not able to comprehend or comply with study requirements~2. Subjects who are pregnant~3. Subjects with BMI \> 40~4. Subjects with autoimmune disorder requiring \>10mg of a corticosteroid per day~5. Subjects with pre-existing systemic infections~6. Subjects with a wound-healing disorder~7. Subjects who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking Alvimopan~8. Subjects who are immunocompromised such as HIV or transplant, or receiving chemo or radiation therapy~9. Subjects with a hernia defect \< 9cm2 large when measured intra-operatively~10. Subjects in which intra-operatively their surgical wound field/wound is characterized as Type 2, 3, or 4 (Appendix II)~11. Subjects in which the ventral incisional hernia repair requires more than one operation to reduce the hernia or to complete the hernia repair~12. Subjects with a hernia repair requiring an emergent procedure~13. Subjects in which untreated cancer was found intra-operatively~14. Subjects with cirrhosis or are currently being treated with dialysis~15. Subjects with severe hepatic impairment (Childs-Pugh class C)~16. Subjects with end-stage renal disease~17. Subjects scheduled for a concomitant procedure that involves the GI tract~18. Subjects with unplanned procedures that involve the GI tract~19. Subjects requiring post-operative NGT~20. Subjects participating in another prospective interventional study that involves the use of a device, drug, or surgery that would compromise the current study~21. Subjects with an epidural to control perioperative pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alvimopan (Entereg) (Type: EXPERIMENTAL): Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
- Suger Pill (Control) (Type: PLACEBO_COMPARATOR): Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.

Based on this trial design, predict the completion outcome and termination type (if applicable).